Blog

Jul 12, 2025, 15:52

A Recent Lancet Article Uncovered Troubling Evidence for Chemotherapy Drugs – NCDconnect

NCDconnect shared a post by IDA Foundation on LinkedIn, adding:

“When essential cancer medicines fail quality tests, it’s not just a system failure, it’s a patient safety issue.

A recent Lancet article uncovered troubling evidence: commonly used chemotherapy drugs like oxaliplatin and doxorubicin failed quality tests in several LMIC markets. And this isn’t an isolated case.

As procurement actors know too well, ensuring availability is only part of the equation. Trust in the product, its quality, consistency, and oversight, is just as critical.

Through our parent organisation IDA Foundation, NCDconnect supports access to oncology medicines backed by stringent quality assurance – from supplier vetting to in-market testing.

Want to understand what’s at stake and how QA systems can protect patients in your supply chain? Read the full blog.”

Quoting IDA Foundation‘s post:

“According to WHO at least 1 in 10 medicines in LMICs are substandard or falsified.

A recent Lancet article has exposed concerning results: widely used chemotherapy drugs like cisplatin and cyclophosphamide failed in-market quality tests in several low- and middle-income countries (LMICs).

These aren’t just numbers. These are patient outcomes at risk.

At IDA Foundation, we understand the risks all too well. That’s why, for over 50 years, we’ve built and refined our quality assurance (QA) systems to detect, prevent, and mitigate these risks. From strict supplier vetting to in-depth testing and continuous monitoring, IDA Foundation remains committed to protecting patients through every step of the supply chain.

To learn more about our approach to quality assurance and how we help ensure access to reliable oncology medicines, read our latest blog.”

More posts featuring NCDconnect and IDA Foundation on Oncodaily.